登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688277 证券简称：天智航 公告编号：2025-037 北京天智航医疗科技股份有限公司 关于参加2025年半年度科创板医疗器械及医疗设备行业 集体业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 会议召开时间：2025年9月17日15:00-17:00 ● 会议召开地点：上海证券交易所上证路演中心（网址：https://roadshow.sseinfo.com/）（以下简称"上 证路演中心"） ● 会议召开方式：上证路演中心网络文字互动 ● 投资者可于2025年9月10日至9月16日16:00前登录上证路演中心网站首页点击"提问预征集"栏目或通 过公司邮箱tinavi@tinavi.com进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 三、参加人员 参加本次业绩说明会的人员有：公司总经理徐进先生、独立董事张瑞君女士、财务总监齐敏女士、董事 会秘书黄军辉先生（如有特殊情况，参会人员可能进行调整）。 四、投资者参加方式 ...

经中国证券监督管理委员会（以下简称"中国证监会"）"证监许可〔2020〕 1001 号文"批准，北京天智航医疗科技股份有限公司（以下简称"公司"或"天 智航"）首次公开发行人民币普通股（A 股）股票 4,190.00 万股。本次公司发行 新股的发行价为 12.04 元/股，募集资金总额为 504,476,000.00 元，扣除发行费用 56,175,293.91 元后，实际募集资金净额为 448,300,706.09 元。本次公开发行股票 于 2020 年 7 月 7 日在上海证券交易所上市。中信建投证券股份有限公司（以下 简称"中信建投证券"或"保荐人"）担任本次公开发行股票的保荐人。 经中国证监会"证监许可〔2022〕797 号文"批准，天智航向特定对象发行 人民币普通股（A 股）股票 29,545,091 股。本次公司发行新股的发行价为 12.53 元/股，募集资金总额为 370,199,990.23 元，扣除发行费用 10,443,396.23 元后， 实际募集资金净额为 359,756,594.00 元。本次公开发行股票于 2023 年 3 月 7 日 在上海证券交易所上市。中信建投证券担任本次向特 ...

证券代码：688277 证券简称：天智航 公告编号：2025-037 北京天智航医疗科技股份有限公司 关于参加 2025 年半年度科创板医疗器械及医疗设备行业 集体业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资者可于 2025 年 9 月 10 日至 9 月 16 日 16:00 前登录上证路演中心网 站首页点击"提问预征集"栏目或通过公司邮箱 tinavi@tinavi.com 进行提问。 公司将在说明会上对投资者普遍关注的问题进行回答。 会议召开时间：2025 年 9 月 17 日 15:00-17:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/）（以下简称"上证路演中心"） 会议召开方式：上证路演中心网络文字互动 北京天智航医疗科技股份有限公司（以下简称"公司"）已于 2025 年 8 月 28 日发布公司 2025 年半年度报告，为便于广大投资者更全面深入地了解公司 ...

Group 1 - The medical device sector is experiencing significant growth, with the CSI All Index Medical Device Index (H30217) rising by 3.31% as of September 8, 2025, and key stocks such as United Imaging Healthcare (688271) increasing by 11.64% [1] - The Medical Device ETF (159883) has seen a notable increase of 8.06 billion CNY in scale over the past month, ranking it among the top 25% of comparable funds [2] - The launch of the "5G Brain-Heart Mobile" platform represents a major breakthrough in the field of brain health, marking the first clinical application of a brain-machine interface for Alzheimer's disease [3] Group 2 - The Chinese medical device industry is poised for international expansion, particularly in the European market, which is valued at 160 billion euros in 2023, with steady growth expected [4] - The medical device sector is anticipated to grow in 2025, driven by increased bidding activity for imaging equipment and supportive policies for home medical devices, alongside accelerated international expansion [4] - The medical device ETF (159883) is the largest in the A-share market, covering various segments including medical equipment and consumables, and is positioned for efficient trading [5]

Group 1: Company Highlights - Mindray Medical launched the world's first clinically implemented critical care AI model and established an animal healthcare subsidiary [1] - Jieshun Technology's cloud-managed SaaS service increased to 16,600 lanes, with software and cloud service revenue reaching 125 million yuan, a year-on-year growth of 26.11% [1] - State Grid Information Technology reported a revenue of 3.525 billion yuan, a decrease of 4.55% year-on-year, while its virtual power plant business is being applied in multiple cities [2] - Inke Recycling focuses on high-value applications of recycled plastics, with significant growth in non-European markets and a projected dividend of 1.00 yuan per 10 shares [3] - ZaiJing Pharmaceutical achieved a revenue of 376 million yuan, a 56% increase, driven by sales growth of its drugs [4] - Tianzhihang reported a revenue of approximately 125 million yuan, a year-on-year increase of 114.89%, with significant growth in orthopedic surgical robot sales [5] - Aibo Medical's revenue reached 787 million yuan, a 14.72% increase, with a gross margin of 65.25% [6] - Mankalon's strategy focuses on expanding its presence in core urban areas and enhancing profitability of franchise stores [7] - Oulu Tong's revenue reached 2.12 billion yuan, a 32.59% increase, with data center power business revenue growing by 94.30% [8] - Sun Paper's special paper project is operational, with plans for further production capacity expansion [9] - Taili Technology is enhancing its market penetration and focusing on customized material solutions for various industries [10] Group 2: Financial Performance - Jieshun Technology's parking asset operation revenue grew by 49.86%, with new orders totaling 677 million yuan [1] - State Grid Information Technology's net profit decreased by 11.01% due to increased corporate income tax [2] - Inke Recycling's non-U.S. market revenue grew by 31.15% year-on-year [3] - ZaiJing Pharmaceutical's new drug approvals are expected to boost future sales [4] - Tianzhihang's orthopedic robot surgeries exceeded 22,000 cases, indicating strong market demand [5] - Aibo Medical's second-quarter revenue was 430 million yuan, a 14.44% increase year-on-year [6] - Oulu Tong's R&D expenses increased by 28.26%, reflecting investment in innovation [8] - Sun Paper's projects are expected to enhance its competitive position in the market [9]

Core Viewpoint - The article discusses the transformation of the domestic surgical robot industry in China, highlighting the shift from reliance on foreign technology to the emergence of local companies that are innovating and competing effectively in the market [4][5]. Group 1: Market Dynamics - The global surgical robot market has been historically dominated by the Intuitive Surgical's "da Vinci" system, which has created significant barriers to entry for other companies due to high prices and maintenance costs [7]. - Domestic companies are leveraging lower prices as a key entry point, with some surgical robots priced at about one-third of the "da Vinci" system [8]. - From 2020 to 2022, the Chinese surgical robot industry saw nearly 100 financing events, with disclosed total financing exceeding 20 billion yuan, indicating strong investor interest [9]. Group 2: Growth Potential - The surgical robot market in China is projected to grow significantly, with an expected market size of 3.84 billion USD by 2026, reflecting a growth rate of 44.3% [10]. - The high profit margins in the industry, with Intuitive Surgical maintaining gross margins around 70% and net margins over 20%, highlight the lucrative nature of this market [10]. Group 3: Challenges and Adjustments - Despite the growth potential, the industry is experiencing a cooling in capital investment, with only nine financing events in 2024, compared to previous years [16]. - The lengthy procurement process in hospitals and limited insurance coverage for robotic surgeries are significant barriers to market penetration [17][18]. - The lack of a comprehensive training system for doctors and unclear liability in case of surgical complications further hinder the adoption of surgical robots [19]. Group 4: Strategic Shifts - Companies are moving away from price competition and focusing on differentiated innovation to build core competencies, as evidenced by advancements in technology and product performance [22]. - There is a strategic shift towards penetrating lower-tier medical markets, with a notable increase in installations in county-level hospitals [24]. - Expanding into international markets is becoming a crucial growth strategy for domestic surgical robot companies, with some achieving significant overseas orders [25][26]. Group 5: Future Outlook - The current capital market cooling is viewed as a new starting point for the industry, emphasizing the importance of long-term value and balancing technology, clinical application, and commercialization [27].

Financial Performance - Company reported a total revenue of 125 million yuan for the first half of 2025, representing a year-on-year increase of 114.89% [1] - The net profit attributable to shareholders was -57.55 million yuan, a decrease of 23.8% compared to the previous year [1] - In Q2 2025, total revenue reached 66.73 million yuan, up 127.21% year-on-year, while the net profit attributable to shareholders was -44.34 million yuan, down 21.75% [1] - Gross margin improved to 73.67%, an increase of 7.05% year-on-year, while net margin was -51.54%, up 35.34% year-on-year [1] - Total expenses (selling, administrative, and financial) amounted to 124 million yuan, accounting for 98.94% of revenue, a decrease of 35.44% year-on-year [1] Cash Flow and Financial Health - The company reported a negative operating cash flow per share of -0.12 yuan, but this was an improvement of 39.12% year-on-year [1] - The average operating cash flow over the past three years was -112.22% of current liabilities, indicating ongoing cash flow challenges [1] - The company’s receivables increased significantly by 157.70% year-on-year, reaching 90.46 million yuan [1] Market Position and Competition - As of the end of Q1 2025, the company has completed over 110,000 surgeries, enhancing its operational experience and understanding of clinical needs [3] - The company has established a product development framework that includes "pre-research, transformation, and market launch," which supports its continuous innovation capabilities [3] - The competitive landscape in the surgical robot market is intense, with 64 companies having 115 approved surgical robot products as of the end of 2024, particularly in the orthopedic segment, which accounts for 47% of the total approved products [2]

证券代码：688277 证券简称：天智航 公告编号：2025-036 北京天智航医疗科技股份有限公司 （一）提前离任的基本情况 ■ （二）离任对公司的影响 根据《中华人民共和国公司法》《北京天智航医疗科技股份有限公司章程》等有关规定，马敏先生的辞 职报告自送达公司董事会之日起生效。其已按公司相关规定做好交接工作，其辞职不会影响公司的正常 运营。截至本公告披露日，马敏先生直接持有公司股份23.10万股。马敏先生辞去公司总裁职务后，将 继续严格遵守《上海证券交易所科创板股票上市规则》《上海证券交易所上市公司自律监管指引第15号 一一股东及董事、高级管理人员减持股份》等相关法律、法规及规范性文件的规定以及2023年限制性股 票激励计划和2024年限制性股票激励计划所作的相关承诺。 马敏先生在任职期间恪尽职守，勤勉尽责，公司及董事会对马敏先生在担任公司总裁期间所作的贡献表 示衷心感谢！ 特此公告。 关于公司高级管理人员离任的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： 北京天智航医疗科技股份有限公司（以下简称" ...

Group 1 - The company Tianzhihang (SH 688277) announced the resignation of its president, Ma Min, effective from August 28, 2025, while he will continue to serve as a non-independent director on the board [1] - For the year 2024, the revenue composition of Tianzhihang is 96.5% from the medical device industry and 3.5% from other businesses [1] - The current market capitalization of Tianzhihang is 8.3 billion yuan [2]

（编辑 楚丽君） 证券日报网讯 8月28日晚间，天智航发布公告称，公司董事会于2025年8月28日收到马敏先生的辞职报 告，马敏先生因工作调整向公司董事会申请辞去公司总裁职务，其辞职后，仍担任公司第六届董事会非 独立董事职务。 ...